Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer's Disease Clinical Trial

Official title: Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Status Terminated

Clinical Trial Summary

The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy subjects.

Clinical Trial Description

The overall research questions to be addressed by this protocol are as follows:

• To assess the dynamic uptake and washout of (123I) MNI-168, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in Alzheimer's (AD) subjects and similarly aged and gender matched healthy controls.

• To perform blood metabolite characterization of (123I) MNI-168 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of (123I) MNI-168 as a single photon computed tomography (SPECT) brain imaging agent.

• To acquire initial safety data following injection of (123I) MNI-168.

• Obtain test/retest reproducibility information in AD subjects with (123I) MNI-168 based on initial studies. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

• NCT number: NCT00870519
• Study type: Interventional
• Source: Institute for Neurodegenerative Disorders
• Status: Terminated
• Phase: Phase 1
• Start date: January 2009
• Completion date: December 2010